Abstract:
As nanotechnology companies move into public markets, early stage companies may lack the revenue visibility usually accompanying startups in more established industries.
It is arguable that a platform technology-based nanotechnology company – what we’ll call pluripotent – deserves a premium valuation: one that exceeds the value of its visible product line. But as shown by the withdrawn IPO of Nanosys – an example of this type of company – public investors may not see it this way.